Clinical Trial

Effects of Neurofeedback Training on Attentional Deficits in Patients With Acquired Brain Injury

Study acronym: NeMoRe
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 7, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to investigate new neuromodulation therapies for attention deficits following acquired brain injury. Brain damage can affect various domains, including motor and cognitive functions. However, cognitive deficits have many consequences on the functionality and independence of patients, and attention is an essential requirement for most of daily activities. After brain damage, cognitive rehabilitation is generally the first treatment option for attention deficits. Some studies have shown that cognitive rehabilitation is sometimes not very effective. For this reason, new therapies such as neuromodulation techniques are being investigated. Neurofeedback is a non-invasive neuromodulation therapy involving a type of computer-based training and learning, and some studies have shown that it is a promising tool to treat cognitive deficits in patients with brain injuries. In the present study, the investigators will evaluate the effects of neurofeedback as a therapy for attentional deficits after brain injury. Participants undergoing neurofeedback and cognitive therapy will be compared to participants only receiving cognitive therapy.
Trial Details
NCT Number NCT06863025
Lead Sponsor Hospitales Nisa
Collaborators: Horizon 2020 - European Commission
Conditions Brain Injuries, Attention Disorder
Enrollment 30 participants
Start Date 2024-10-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-07